作者
Sara J Ireland, Alyssa A Guzman, Dina E O’Brien, Samuel Hughes, Benjamin Greenberg, Angela Flores, Donna Graves, Gina Remington, Elliot M Frohman, Laurie S Davis, Nancy L Monson
发表日期
2014/11/1
期刊
JAMA neurology
卷号
71
期号
11
页码范围
1421-1428
出版商
American Medical Association
简介
Importance
This study describes what is, to our knowledge, the previously unknown effect of glatiramer acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).
Objective
To determine whether glatiramer acetate therapy normalizes dysregulated B-cell proliferation and cytokine production in patients with MS.
Design, Setting, and Participants
Twenty-two patients with MS who were receiving glatiramer acetate therapy and 22 treatment-naive patients with MS were recruited at The University of Texas Southwestern Medical Center MS clinic. Cell samples from healthy donors were obtained from HemaCare (Van Nuys, California) or Carter Blood Bank (Dallas, Texas). Treatment-naive patients with MS had not received any disease-modifying therapies for at least 3 months before the study.
Exposures
Glatiramer acetate therapy for at least 3 months at the time of the study.
Main Outcomes and …
学术搜索中的文章
SJ Ireland, AA Guzman, DE O'Brien, S Hughes… - JAMA neurology, 2014